Eli Lilly and Johnson & Johnson are suing the U.S. government over rejected changes to the 340B drug discount program. The program aims to provide discounted drugs to lower-income medical facilities. The drugmakers propose selling drugs at full price with rebates later to prevent misuse and enhance transparency.